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Immune cells infiltrate adipose tissues and provide a framework to
regulate energy homeostasis. However, the precise underlying
mechanisms and signaling by which the immune system regulates
energy homeostasis in metabolic tissues remain poorly under-
stood. Here, we show that the AT-rich interactive domain 5A
(Arid5a), a cytokine-induced nucleic acid binding protein, is impor-
tant for the maintenance of adipose tissue homeostasis. Long-term
deficiency of Arid5a in mice results in adult-onset severe obesity. In
contrast, transgenic mice overexpressing Arid5a are highly resistant
to high-fat diet-induced obesity. Inhibition of Arid5a facilitates the
in vitro differentiation of 3T3-L1 cells and fibroblasts to adipocytes,
whereas its induction substantially inhibits their differentiation.
Molecular studies reveal that Arid5a represses the transcription of
peroxisome proliferator activated receptor gamma 2 (Ppar-γ2) due
to which, in the absence of Arid5a, Ppar-γ2 is persistently expressed
in fibroblasts. This phenomenon is accompanied by enhanced fatty
acid uptake in Arid5a-deficient cells, which shifts metabolic homeo-
stasis toward prolipid metabolism. Furthermore, we show that
Arid5a and Ppar-γ2 are dynamically counterregulated by each other,
hence maintaining adipogenic homeostasis. Thus, we show that
Arid5a is an important negative regulator of energy metabolism
and can be a potential target for metabolic disorders.
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Asignificant population of metabolic tissues consists of im-mune cells, comprising mainly macrophages and lympho-
cytes. Although this evolutionarily conserved anatomical
relationship was noticed long ago, the diverse roles of immune
cells in metabolic tissue have remained poorly understood. A
widely accepted traditional role of immune cells in metabolic
tissue is to defend the tissue against pathogens. Apart from this
role, emerging evidence indicates that immune cells dictate en-
ergy homeostasis (1). Particularly, cytokines secreted by immune
cells have been shown to participate in energy regulation during
physiological and pathological conditions (2). During exercise,
interleukin 6 (IL-6) and transforming growth factor β are pro-
duced, improving glucose and fat metabolism (3). Moreover,
during cancer cachexia and infectious conditions, excess pro-
duction of cytokines drastically increases energy consumption,
often resulting in weight loss (4). In contrast, cytokine deficiency
or inhibition, particularly of IL-6, have been reported to lead to
the development of obesity in mice and humans (5, 6). While
several lines of evidence suggest that infiltrated immune cells
induce chronic low-grade inflammation in adipose tissues, which
might be the cause of metabolic disorders such as insulin resis-
tance, recent evidence suggests that low-grade inflammation pro-
vided by cytokines in metabolic tissue is actually not bad but,
rather, is a part of normal physiology that is necessary to maintain
adipogenic homeostasis (7). Although several in vitro and in vivo
studies have provided a strong foundation demonstrating that cy-
tokines regulate energy metabolism, the precise underlying mech-
anisms and signaling by which cytokines play a role in maintaining
energy homeostasis are poorly understood.
AT-rich interactive domain 5a (Arid5a) is a member of the
ARID protein family (8). It is rapidly expressed within a few
hours upon activation of TLR4 signaling and upon direct stim-
ulation by several cytokines, mainly IL-6 and IL-17 (9, 10). Arid5
proteins were initially discovered as a protein bound to the
transcriptional modulator region of the human cytomegalovirus
major immediate-early promoter (11). Recently, we discovered
that Arid5a stabilizes messenger RNA of IL-6 by competing with
IL-6 mRNA destabilizer Regnase1, resulting in stabilization of
the IL-6 concentration in vivo over a longer period (12). Subse-
quently, we demonstrated its ability to stabilize several other
mRNAs, including Stat3, Tbet, and Ox40, by binding to their 3
prime untranslated regions (3′UTRs) (13–15). Furthermore,
we revealed its critical involvement in the inflammation milieu.
Arid5a-deficient mice are resistant to experimental autoimmune
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encephalomyelitis (EAE), bleomycin-induced lung injury, and
septic shock (12, 15, 16).
In this article, we demonstrate a critical role for Arid5a in the
regulation of energy homeostasis in adipose tissues. Modulation of
Arid5a expression in vitro and in vivo severely affects adipogenesis
and obesity, respectively, through the modulation of peroxisome
proliferator activated receptor gamma 2 (Ppar-γ2) expression.
Results
Long-Term Genetic Deficiency of Ari5da in Mice Results in Adult-Onset
Obesity. Utilizing the Arid5a−/− mice, we investigated the possi-
ble role of Arid5a in metabolism (12). Under normal conditions
and feeding with normal chow containing 4.5% crude fat, female
Arid5a−/− mice were phenotypically comparable in body size and
weight to their wild-type (Wt) counterparts up to several weeks
of age. However, after 15 to 20 wk, in comparison with Wt mice,
female Arid5a−/− mice slowly started to gain weight continuously
over time (Fig. 1A). At ∼30 to 35 wk of age, the difference be-
came very clear in Arid5a−/− mice, measuring ∼30% higher than
their Wt counterpart females (Fig. 1A). At 2 y of age, Arid5a−/−
mice became severely obese, weighing up to 70 g, which is more
than twice the weight of average Wt mice that age (Fig. 1 B and
C). In addition to a maximum amount of accumulated fat in the
visceral area, adipose tissue appeared to be increased all over the
body in Arid5a−/− mice (SI Appendix, Fig. S1A). Histochemical
analysis revealed a similar size of adipocytes in Arid5a−/− fat tissue,
suggesting an increase in hyperplasia but not hypertrophy in
Arid5a −/− mice (SI Appendix, Fig. S1B). In addition, Arid5a−/−
mice developed severe fatty liver compared with Wt mice (SI Ap-
pendix, Fig. S1C). The serum levels of several adipokines, including
leptin and total cortisol, were significantly increased in obese
Arid5a−/− mice (SI Appendix, Fig. S1 D and E). This adult-onset
obesity was also observed in male mice (SI Appendix, Fig. S2A).
Obesity is often associated with glucose metabolic disorders.
While no significant differences in serum glucose were found
between Wt and Arid5a−/−mice at a young age (10 to 12 wk), old
Arid5a−/− mice (age 50 to 60 wk) had slightly increased serum
glucose levels compared with Wt mice the same age (SI Ap-
pendix, Fig. S2B). The glucose tolerance test (GTT) revealed that
compared with Wt mice, Arid5a−/− mice required more time to
clear the serum glucose level (SI Appendix, Fig. S2C). Moreover,
the insulin tolerance test (ITT) also suggested that old Arid5a−/−
mice had increased resistance to insulin (SI Appendix, Fig. S2D).
These data for ITT and GTT revealed that obese Arid5a−/− mice
had some defects in glucose clearance from serum, suggesting
some defects in glucose metabolism.
Since the development of obesity in Arid5a−/− mice was ob-
served at a late age on a normal low-fat diet, we next investigated
whether Arid5a−/− mice were more vulnerable to obesity at an
early age by feeding a high-fat diet. We fed a high-fat diet (con-
taining 32% crude fat, ∼60% calories from fat) to young mice
(8 wk old) for 12 wk. Arid5a−/− mice gained weight more rapidly
thanWt, but after a few weeks, no significant difference was observed
between Wt and Arid5a−/− (Fig. 1D). However, on a diet con-
taining a moderately high amount of fat similar to the human diet
(14% crude fat, ∼25% calories from fat), both male and female
Arid5a−/− mice became obese within 10 to 15 wk compared with
Wt mice (Fig. 1E and SI Appendix, Fig. S2E). These data clearly
suggest Arid5a protects against obesity development during the
low and moderately high fat fed condition.
We next examined the effect of overexpressing Arid5a during
obesity development. We developed transgenic mice that over-
express Arid5a (Tg-Arid5a) (17). Under normal conditions, these
Tg-Arid5a mice exhibit size and weight comparable to those of Wt
mice (SI Appendix, Fig. S2F). Interestingly, when subjected to a
high-fat diet (containing 32% crude fat, ∼60% calories from fat),
they are highly resistant to weight gain. While Wt mice and
Arid5a−/− mice gain ∼80 to 90% weight in 12 wk, Tg-Arid5a mice
gain only ∼10 to 15% weight (Fig. 1F). These data suggest that
Arid5a protects against obesity development.
Arid5a Negatively Regulates the Adipogenic Program. To explore
the mechanism of obesity development in Arid5a−/− mice, we
examined whether the adipogenesis process was modulated by
Arid5a. To achieve this goal, first, we developed Arid5a−/− and
Arid5a-overexpressing stable cell lines of 3T3-L1 origin. Then,
we monitored the kinetics of adipogenesis in vitro (from day
0 to day 7) in these Arid5a-deleted or -overexpressing cells. The
accumulation of fatty acids as lipid droplets was clearly visible
within 3 d in 3T3-L1 Arid5a−/− cells, while very few or no lipid
droplets were observed in Wt and Arid5a-overexpressing cells
(Fig. 2 A, a–f and SI Appendix, Fig. S3A). At approximately day 5,
lipid droplets were visible in both Wt and Arid5a−/− cells, but the
frequency and size of the lipid droplets in Arid5a−/− cells were
clearly larger than in Wt cells (Fig. 2 A, g–i). Interestingly, at this
time point in Arid5a-overexpressing cells, very little or no lipid
droplets were formed (Fig. 2 A, i and SI Appendix, Fig. S3A). At
around day 7, both Wt 3T3-L1 and Arid5a−/− cells developed into
oval-shaped adipocytes with clear visible lipid droplets (stained
red) (Fig. 2 A, j and k). However, the size of the adipocytes and
lipid droplets in Arid5a−/− cells were significantly larger than in Wt
cells. In comparison with Wt and Arid5a−/− cells, very few lipid
droplets were visible in Arid5a-overexpressing cells, and most
importantly, the cell size had not expanded at all (Fig. 2 A, j–l and
SI Appendix, Fig. S3A). We also monitored the adipogenesis
process in mouse embryonic fibroblasts (MEF) cells derived from
Wt and Arid5a−/− mice. In response to the same stimulants used
for 3T3-L1 cells, MEF cells from Wt mice exhibited rare or no
conversion of adipocytes up to day 10, but interestingly, a large
number of Arid5a−/−MEF cells had converted to adipocytes (Fig.
2B and SI Appendix, Fig. S3B). Moreover, several adipokines,
mainly adiponectin and resistin, were highly increased in the
lysates of Arid5a−/− cells compared with Wt cells at day 10 of
adipogenesis (SI Appendix, Fig. S3C). These data clearly indicate
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Fig. 1. Arid5a deficiency develops adult-onset obesity. (A) Monitoring of
the total body weight of Wt and Arid5a−/− mice with normal chow (4.5%
crude fat amount), n = 8 to 10. This experiment was repeated 3 times. (B)
Weight comparison of old female Arid5a−/− and Wt mice (age: 18 to 24 mo,
n = 12). (C) Representative images of female Wt and Arid5a−/− mice (age 18
to 24 mo). (D) Total weight monitoring after mice were fed a high-fat diet
(HFD) (32% crude fat), n = 8 to 10. (E) Total weight monitoring after mice
were fed moderate fat (14% crude fat) n = 8 to 10. (F) Total weight moni-
toring in Wt, Arid5a−/−, and Tg-Arid5a mice after they were fed a high-fat diet
(32% crude fat; 2 independent experiments were performed). An unpaired
Mann–Whitney U test was performed for statistical analysis. Error bars repre-
sent means ± SD (**P < 0.01; ***P < 0.001, ****P < 0.0001; ns, not significant).
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that Arid5a deletion enhances the adipogenesis process, while its
overexpression inhibits adipogenesis.
IL-6 is known to inhibit the differentiation of adipogenesis. As
expected, we also observed that IL-6 inhibited the differentiation
of adipogenesis in Wt cells; however, IL-6 could not inhibit the
differentiation in Arid5a−/− cells, indicating that IL-6 utilized
Arid5a to inhibit adipogenesis (Fig. 2C).
Arid5a Inhibition Enhances the Process of Lipid Anabolism. We next
investigated the possible mechanisms of Arid5a-mediated mo-
lecular and biochemical effects in lipid metabolism. Physiologi-
cally, adipogenesis occurs in the stromal vascular environment.
RNA sequencing analysis of the stromal vascular fraction (SVF)
of Wt and Arid5a−/− mice revealed that several genes related to
lipid metabolism, including the master regulator of adipogenesis
Ppar-γ, were enhanced by Arid5a deletion (SI Appendix, Fig.
S4A). RT-PCR analysis confirmed the enhanced mRNA expres-
sion of Ppar-γ in the SVF of Arid5a−/− mice (Fig. 3A). Consistent
with the SVF data, Ppar-γ appeared to be greatly influenced by
changes in Arid5a protein expression in 3T3-L1 and MEF cells
during adipogenesis. The Ppar-γ protein has 2 distinct isoforms,
Ppar-γ1 and Ppar-γ2, of which Ppar-γ2 is important during the
process of adipogenesis (18). In Arid5a−/− cells, mRNA expression
of Ppar-γ2 was significantly elevated at early time points of
adipogenesis in comparison with Wt cells of both 3T3-L1 and
MEF origin (Fig. 3 B and C). The increased mRNA level of
Ppar-γ2 in Arid5a−/− cells was clearly reflected in the protein
level at all of the time points of adipogenesis in MEF cells and
on day 7 of adipogenesis in 3T3-L1 cells (Fig. 3D). However, in
Arid5a-overexpressing 3T3-L1 cells, Ppar-γ2 expression was
significantly suppressed compared with Wt and Arid5a−/− 3T3-L1
cells at all time points of adipogenesis (Fig. 3D). Instead, in
Arid5a-overexpressing 3T3-L1 cells, Ppar-γ1 appeared to be
enhanced on day 7 of adipogenesis (Fig. 3D). These data show
that Arid5a inhibits lipid metabolism, possibly through regulating
the Ppar-γ2 isoform. Ppar-γ is known to increase mitochondrial
membrane potential and biogenesis (19). Consistently, we ob-
served increased mitochondrial activity and numbers in Arid5a−/−
compared with Wt cells (SI Appendix, Fig. S4B). In addition to
Ppar-γ2, mRNA expression of the lipid uptake molecules Fabp4
and Cd36 was also significantly increased during adipogenesis
upon Arid5a deletion (Fig. 3 E and F). In contrast, Arid5a-
overexpressing 3T3-L1 cells had significantly lower expression of
these genes (Fig. 3 E and F). The increased expression of CD36
and FABP4 by Arid5a deletion was confirmed at the protein level
in both 3T3-L1 and MEF cells by fluorescence-activated cell
sorting (FACS) and Western blot analysis, respectively (Fig. 3 G
and H). Moreover, the lipid uptake function was also increased in
Arid5a-deleted 3T3-L1 cells under normal conditions and early
adipogenesis (Fig. 3I). Overall, we show that the absence of
Arid5a enhances the process of lipid anabolism.
Arid5a Represses the Transcription of Ppar-γ2. As we showed that
Ppar-γ2, a master regulator of lipid metabolism, is largely en-
hanced by Arid5a deletion during adipogenesis, we next in-
vestigated the relationship between Ppar-γ2 and Arid5a at the
molecular level. Arid5a is a nucleic acid binding protein with the
ability to modulate both transcriptional and posttranscriptional
processes. While Arid5a localizes in the nucleus under normal
conditions, after receiving an inflammatory signal, it is trans-
ported to the cytoplasm and then, upon resolution of the in-
flammation, back to the nucleus via the importin-α/B pathway
(17). In 3T3-L1 cells, we found that Arid5a was localized mostly
in the nucleus under normal conditions and in the early phase
(day 3) of adipogenesis (SI Appendix, Fig. S5A). We analyzed the
effects of Arid5a on the promoter activity of Ppar-γ2 by the lu-
ciferase assay during adipogenesis. Ppar-γ2 promoter activity
increased significantly during early adipogenesis compared with
normal conditions, but the addition of an Arid5a-expressing
plasmid significantly decreased the promoter activity of Ppar-γ2,
suggesting that Arid5a repressed the transcription of Ppar-γ2 (Fig.
4A). We next performed the promoter deletion experiment to
identify the Arida5a regulatory region in the Ppar-γ2 promoter.
We prepared Ppar-γ2 promoter vectors of several lengths starting
from 1,000 to 150 base pair (bp) upstream from the transcription
initiation site. The promoter activity of Ppar-γ continued to de-
crease with shortening of the promoter, but the promoter activity
was still significantly decreased in the presence of Arid5a up to
350 kb of the Ppar-γ2 promoter (Fig. 4B). These data suggest that
Arid5a inhibits the transcription of Ppar-γ2 during the early adi-
pogenesis process by modulating the proximal Ppar-γ2 promoter.
We next analyzed the promoter sequence of Ppar-γ2 in detail.
Arid5a binds to the AATATT or AATACT region of nucleic
acid (SI Appendix, Fig. S5B). We found these Arid5 binding sites
(highlighted in yellow) in several regions of the Ppar-γ2 pro-
moter of mice and humans within 500 bp upstream of the tran-
scription initiation site (SI Appendix, Fig. S5 C and D). Of note,
both in mice and humans, the Ppar-γ2 gene Arid5a binding site is
placed immediately after the CEBP site, a transcription factor
that is important for the activation of Ppar-γ2 transcription (SI
Appendix, Fig. S5 C and D; indicated in bold letters). To confirm
the binding of Arid5a in Ppar-γ2 during adipogenesis, we per-
formed qPCR analysis to identify the Arid5a-bound promoter
fragments of Ppar-γ2 prepared by chromatin immunoprecipita-
tion analysis. During early adipogenesis, the promoter region of
270 to 430 bp upstream of the transcription initiation site was
highly amplified in comparison with the immunoglobulin G (IgG)
control (Fig. 4C). All these experiments clearly show that Arid5a
can directly modulate the promoter of Ppar-γ2 and repress the
transcription of Ppar-γ during adipogenesis.
Arid5a and Ppar-γ2 Counterregulate Each Other to Maintain Metabolic
Homeostasis. Since expressing Arid5a in 3T3-L1 cells inhibited
adipogenesis and Arid5a−/− cells have enhanced adipogenesis,
we hypothesized that the intrinsic Arid5a in fibroblasts or
preadipocytes should be inhibited for effective adipogenesis. We
observed a gradual decrease in the mRNA expression of Arid5a
during the adipogenesis process (Fig. 5A). However, Ppar-γ2 ex-
pression was simultaneously observed to increase (Fig. 5B),
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Fig. 2. Arid5a negatively regulates adipogenic differentiation. (A) Micro-
scopic image of lipid-stained (red) cells during the monitoring of the adipogenesis
process in Wt (empty vector), Arid5a−/−, and Arid5a-overexpressing (OvEx)
3T3-L1 cells. Cells were subjected to adipogenesis as described in Materials
and Methods. On days 0, 3, 5, and 7, the cells were fixed, stained with red oil
O stain, and counterstained with hematoxylin, and phase contrast images
were taken with a microscope. (B) Microscope images of Wt and Arid5a−/−
MEF cells on days 0 and 10 of adipogenesis. (C) Microscopic images of Wt
and Arid5a−/− 3T3-L1 cells on day 7 of adipogenesis in the presence of IL-6
(10 ng/mL) or phosphate buffered saline (PBS).
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indicating that Arid5a and Ppar-γ2 acted reciprocally during
the adipogenesis process. Hence, we hypothesized that some
molecules that are involved in adipogenesis should be inhibiting
the intrinsic expression of Arid5a. We analyzed the direct effect
of dexamethasone, 3-isobutyl-1-methylxanthine (IBMX), insulin,
and rosiglitazone, which are used to induce adipogenesis in vitro.
Of these compounds, rosiglitazone, a strong inducer of Ppar-γ,
inhibited the expression of Arid5a (Fig. 5C). This effect was con-
firmed by troglitazone, another inducer of Ppar-γ, which also
showed an inhibitory effect on Arid5a expression (Fig. 5D). As
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Fig. 3. Arid5a deletion enhances the process of lipid anabolism. (A) Ppar-γ expression (mRNA) in SVF collected from 24 wk old female Wt and Arid5a−/− mice. (B)
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expressions of target gene at all time points were normalized with the day 0 Wt cell value. All mRNA experiments and Western blot analyses were repeated at least
twice. An unpaired Student’s t test was performed for statistical analysis. Error bars show the means ± SEM (*P < 0.05; **P < 0.01; ***P < 0.001; ns, not significant).
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expected, the decreased expression of Arid5a by rosiglitazone was
also observed at the protein level (Fig. 5E). These data indicate
that Ppar-γ itself can inhibit the expression of Arid5a to enhance its
up-regulation. Consistently, when Ppar-γ2 was forcibly expressed
in the Arid5a-overexpressing 3T3-L1 cell line, the inhibitory
adipogenic effect was significantly reversed (Fig. 5F). These data
indicate that Ppar-γ has the capacity to inhibit Arid5a and Arid5a-
mediated inhibition of adipogenesis.
We next analyzed how Ppar-γ2 could inhibit Arid5a expression.
Previously, we showed that Arid5a is induced through the nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-κB)
pathway during LPS stimulation and that the induced Arid5a is
quickly degraded through the E3 ligase/ubiquitin pathway (10). It is
well known that Ppar-γ inhibits the NF-κB pathway, and it was
recently discovered that Ppar-γ is an E3 ligase that can directly
degrade the p65 component of the NF-κB complex (20–22). Hence,
we analyzed whether Ppar-γ could limit Arid5a by inhibiting NF-κB
signaling. Supporting our previous findings, upon inhibition of NF-κB
signaling by the IκB kinase (IKK) inhibitor BMS-345541, the
mRNA and protein expression of Arid5a were significantly de-
creased in 3T3-L1 and MEF cell lines (Fig. 5 G–I). This result
suggests that Arid5a expression in fibroblasts is maintained by
NF-κB and that Ppar-γ can inhibit Arid5a by inhibiting NF-κB
signaling.
Collectively, these data indicate that although Arid5a can re-
press the transcription of Ppar-γ2, Ppar-γ2 counterregulates
Arid5a by controlling NF-κB signaling during adipogenesis.
Hence, for effective adipogenesis, Arid5a might be inhibited,
which is accomplished by causing Ppar-γ2 to induce itself and
facilitate adipogenesis. In contrast, to limit excess adipogenesis
and maintain homeostasis, Ppar-γ2 should be checked, which is
accomplished by Arid5a (SI Appendix, Fig. S6).
Discussion
Obesity is becoming an epidemic problem worldwide. Manipu-
lation of energy programming by targeting the associated regu-
lators is a promising therapeutic strategy to control obesity (23).
Here, we report that Arid5a is an important regulatory protein of
energy metabolism that can significantly modulate the process of
adipogenesis in vitro and obesity in vivo.
Adipogenesis is a biologically evolved process to form adipo-
cytes, which have several purposes, of which the main purpose is
to store excess energy that is intended to be used during an energy
crisis. Considering the increased nutrient intake and reduced energy
expenditure in the modern world, our bodies have a propensity to
store the maximum surplus energy, which might lead to obesity.
Hence, a restriction mechanism is required to limit excess adipo-
genesis and maintain adipose tissue homeostasis (24). However, the
precise regulatory mechanism of this adipose tissue homeostasis is
poorly understood. Adipogenesis occurs in the stromal vascular
environment where several types of cells, including immune cells
(mainly macrophages and endothelial cells), are also present to a
large extent. This study and several others have suggested that cy-
tokines, including IL-6 secreted by immune cells and mature adi-
pocytes, play a role in limiting adipogenesis and obesity (3, 25–27).
Cytokines, mainly IL-6 and IL-17, induce Arid5a, which can further
limit the differentiation of new fibroblasts to adipocytes by regulat-
ing Ppar-γ, hence maintaining adipose tissue homeostasis. Together
with several previous reports, we also observed that IL-6 inhibited
the differentiation of adipogenesis; however, IL-6 could not inhibit
the differentiation in Arid5a−/− cells, indicating that IL-6 utilized
Arid5a to inhibit adipogenesis. We previously showed that Arid5a
extends the half-life of IL-6 by stabilizing IL-6 mRNA and hence
increasing the levels of IL-6 in vivo. Although the mechanism is not
clear, a few studies have reported that IL-6-deficient mice develop
adult-onset obesity, suggesting that IL-6 is directly or indirectly re-
quired to restrict the excessive formation of fat cells (6, 28, 29). As a
strong inducer of Arid5a, it is highly likely that IL-6-deficient mice
have insufficient activation of Arid5a, resulting in unrestricted
adipogenesis and leading to obesity. Thus, our findings suggest
that IL-6 inhibit adipogenesis and obesity by activating Arid5a.
One major finding of this paper is the negative regulation of
Ppar-γ2 expression by Arid5a. The obesity development in Arid5a−/−
mice, enhanced adipogenesis in Arid5a−/− cells, and increased ex-
pression of the fat uptake molecules CD36 and FABP4 can be
explained to a large extent by the known effects of Ppar-γ on lipid
metabolism. Ppar-γ promotes lipid uptake and lipid biosynthesis,
hence enhancing the adipogenesis program (30). Moreover, in-
creased Ppar-γ activity is associated with weight gain in both humans
and mice (31, 32). Patients taking Ppar-γ-inducing antidiabetic
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other. (A and B) mRNA expression of Arid5a (A) and
Ppar-γ (B) during adipogenesis in 3T3-L1 cells mea-
sured at different time points during the adipogenesis
process. (C and D) mRNA expression of Arid5a after
treating 3T3-L1 cells with rosiglitazone (50 μM) (C)
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points. (E) Arid5a protein expression levels in 4T1
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Arid5a-overexpressing stable 3T3-L1 cells were tran-
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subjected to adipogenesis and analyzed qualitatively
for adipocyte differentiation on day 7, as described
in Materials and Methods. The images shown are
200× magnified cells and the red stain denotes the
lipid droplets. (G and H) mRNA expression of Arid5a
after treating 3T3-L1 cells (G) and MEF cells (H) with
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points. (I) Arid5a protein expression level in the lysate
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ments were performed at least twice. n = 4 to 5 for
mRNA analysis. An unpaired 2-tailed Student’s t test
was performed for statistical analysis. Error bars show
the means ± SEM (**P < 0.01; ***P < 0.001; ****P <
0.0001; ns, not significant).
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thiazolidinediones have been reported to gain significant weight (31,
33). Recently, it was reported that neuronal Ppar-γ plays a role in
promoting obesity in mice (32). Moreover, Ppar-γ is widely reported
to exert anti-inflammatory effects in cases of septic shock, EAE, and
bleomycin-induced lung injury (34–36). Interestingly, our previous
findings have revealed the Arid5a−/− mice are resistant to those
diseases (12, 15, 16), suggesting a connection of Ppar-γ and Arid5a.
To date, we understand that Arid5a is localized in the nucleus
under noninflammatory conditions, but it is translocated to cy-
toplasm after an inflammatory signal to exert RNA-stabilizing
functions (17). The Ppar-γ2-repressing activity of Arid5a appears
to occur in the nucleus. Arid5a binds to the Ppar-γ2 promoter at
the AATATT sequence adjacent to the CCAAT sequence,
the binding site of CEBP, which is another master regulator of
adipogenesis. Binding of CEBPs is important for Ppar-γ2 activation
during adipogenesis (37). Arid5a binding to Ppar-γ2 might mask
the binding of CEBP to the Ppar-γ2 promoter, preventing the
activation of Ppar-γ2 transcription. It is likely that Arid5a forms a
complex with other proteins to repress Ppar-γ2 transcription.
Arid5a has been reported to bind physically to Sox9 and direct the
process of chondrogenesis (38). Recently, it was reported that
Sox9 must be inhibited for effective adipogenesis (39). These data
indicate that a complex consisting of Arid5a, Sox9, and other
unknown proteins might be necessary for the binding of Arid5a to
DNA and repression of Ppar-γ2 under physiological conditions.
In conclusion, the findings in this paper introduce Arid5a as a
novel and important component of energy homeostasis. Arid5a
restricts the process of adipogenesis. Thus, to facilitate the for-
mation of adipocytes, Arid5a is inhibited by Ppar-γ in the early
stage of adipogenesis (SI Appendix, Fig. S6). Once sufficient adi-
pocytes are formed, mature adipocytes along with infiltrated im-
mune cells secrete IL-6 and other cytokines, which, through
inducing Arid5a, further limit the differentiation of adipocytes (SI
Appendix, Fig. S6). Hence, the coordinated activity of Ppar-γ2 and
Arid5a maintains metabolic homeostasis in adipose tissue.
Materials and Methods
Mice and Ethical Permissions. All mice were housed in the animal house of
Frontiers of Biomedical Science (FBS), OsakaUniversity.Miceweremaintained
in a specific pathogen-free facility with a 12 h/12 h light/dark cycle and free
access to food and water. Unless mentioned otherwise, the mice were fed
standard chow containing a total amount of 4.5% crude fat. Wt C57bl/6j mice
were initially purchased from CLEA Japan and further bred at the FBS animal
facility. Arid5a −/− and Arid5a-overexpressing transgenic (Tg-Arid5a) mice
were generated on the C57bl/6j background as previously described (12, 17).
All experiments were performed in accordance with the guidelines ap-
proved by the institutional animal care and use committee of the Graduate
School of Frontier Biosciences, Osaka University.
Statistical Analysis.All datawere analyzedwithMicrosoft Excel andGraphPad
Prism version 6. Data are expressed as the mean ± SEM for in vitro experi-
ments and mean ± SD for in vivo experiments. For in vitro experiments, the
difference between groups was determined using an unpaired 2-tailed
Student’s t test. For in vivo weight studies, the difference between groups
was determined by a 2-tailed Mann–Whitney U test. For all statistical anal-
yses, P values < 0.05 were considered statistically significant.
Extended methods and information about cell lines, plasmids, stable cell
line preparation, histology, qRT-PCR, adipogenesis, red oil O staining, lipid
quantification, high-fat diet studies, ITT, GTT, total steroid measurement and
fatty acid uptake assay, Arid5a localization (immunofluorescence), FACS anal-
ysis,Western blot, luciferase activity, chromatin immunoprecipitation assay, and
RNA sequencing are described in SI Appendix.
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